Xiao Ping Ye
Vorsitzender bei HANGZHOU TIGERMED CONSULTING CO., LTD
Vermögen: 1 447 Mio $ am 30.04.2024
Profil
Derzeit ist Xiao Ping Ye Chairman & General Manager bei Hangzhou Tigermed Consulting Co., Ltd. Dr. Ye ist außerdem Mitglied des Vorstands der Dian Diagnostics Group Co. Ltd., Coland Holdings Ltd., Shanghai Guochuang Pharmaceutical Co. und HBM Holdings Ltd. Dr. Ye war zuvor Chief Medical Officer von Roche (China) Co. Ltd. Er erhielt einen Doktortitel von der Universität Oxford.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
30.06.2023 | 132 929 656 ( 74,09% ) | 1 085 Mio $ | 30.04.2024 | |
01.02.2024 | 44 309 885 ( 7,78% ) | 362 Mio $ | 30.04.2024 |
Aktive Positionen von Xiao Ping Ye
Unternehmen | Position | Beginn |
---|---|---|
COLAND HOLDINGS LIMITED | Direktor/Vorstandsmitglied | 05.12.2010 |
HANGZHOU TIGERMED CONSULTING CO., LTD | Vorsitzender | - |
HBM HOLDINGS LIMITED | Direktor/Vorstandsmitglied | 01.12.2020 |
Ehemalige bekannte Positionen von Xiao Ping Ye
Unternehmen | Position | Ende |
---|---|---|
DIAN DIAGNOSTICS GROUP CO.,LTD. | Direktor/Vorstandsmitglied | 01.12.2022 |
Shanghai Guo Chuang Pharmaceutical Co., Ltd.
Shanghai Guo Chuang Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Guo Chuang Pharmaceutical Co., Ltd. principally engages in the research, development, production, and sale of pharmaceutical products. Its products include pharmaceuticals against nervous system diseases, digestive system diseases, cardiovascular diseases, mental diseases, and immune system diseases. The company was founded on March 20, 2003 and is headquartered in Shanghai, China. | Direktor/Vorstandsmitglied | 01.10.2021 |
Shanghai LIDE Biotech Co. Ltd.
Shanghai LIDE Biotech Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai LIDE Biotech Co. Ltd. is a translational medicine service provider that specializes in oncology translational research and immuno oncology. The private company is based in Shanghai, China. The Chinese company has a growing bank of over 50 cell line-derived xenograft (cdx) mouse models that are used for preclinical drug efficacy testing. The benefits of cdx models are their cost effectiveness, fast turnaround time, and high efficiency of xenotransplantation. LIDE's FGI (Functional Genomic Imaging) platform leverages its K-cell technology and bioinformatics team to deliver next-generation transcription analysis. The primary benefit of CR (Conditionally Reprogrammed) cells is their intratumor and intertumor heterogeneity, even after amplification. | Direktor/Vorstandsmitglied | - |
Hangzhou Tigermed Consulting Co., Ltd
Hangzhou Tigermed Consulting Co., Ltd Medical/Nursing ServicesHealth Services Tigermed Consulting Co., Ltd. is a Contract Research Organization (CRO) in China that provides regulatory service, Phase I-IV clinical trials, data management & biostatistics, medical translations and GCP training services for healthcare products. The company was founded in 2002 and is headquartered in Shanghai, CN. | Direktor/Vorstandsmitglied | - |
Roche (China) Co. Ltd. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Xiao Ping Ye
University of Oxford | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
HANGZHOU TIGERMED CONSULTING CO., LTD | Commercial Services |
HBM HOLDINGS LIMITED | Health Technology |
DIAN DIAGNOSTICS GROUP CO.,LTD. | Health Services |
Private Unternehmen | 5 |
---|---|
Coland Holdings Ltd.
Coland Holdings Ltd. Pharmaceuticals: MajorHealth Technology Coland Holdings Ltd. engages in the research, development, and sale of generic and traditional Chinese medicine, biochemical drugs, and medical equipment. It focuses on the treatment of hepatobiliary, respiratory system, tumor, and cardiovascular problems. The company was founded on March 23, 2010 and is headquartered in Shanghai, China. | Health Technology |
Shanghai Guo Chuang Pharmaceutical Co., Ltd.
Shanghai Guo Chuang Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Guo Chuang Pharmaceutical Co., Ltd. principally engages in the research, development, production, and sale of pharmaceutical products. Its products include pharmaceuticals against nervous system diseases, digestive system diseases, cardiovascular diseases, mental diseases, and immune system diseases. The company was founded on March 20, 2003 and is headquartered in Shanghai, China. | Health Technology |
Roche (China) Co. Ltd. | |
Hangzhou Tigermed Consulting Co., Ltd
Hangzhou Tigermed Consulting Co., Ltd Medical/Nursing ServicesHealth Services Tigermed Consulting Co., Ltd. is a Contract Research Organization (CRO) in China that provides regulatory service, Phase I-IV clinical trials, data management & biostatistics, medical translations and GCP training services for healthcare products. The company was founded in 2002 and is headquartered in Shanghai, CN. | Health Services |
Shanghai LIDE Biotech Co. Ltd.
Shanghai LIDE Biotech Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai LIDE Biotech Co. Ltd. is a translational medicine service provider that specializes in oncology translational research and immuno oncology. The private company is based in Shanghai, China. The Chinese company has a growing bank of over 50 cell line-derived xenograft (cdx) mouse models that are used for preclinical drug efficacy testing. The benefits of cdx models are their cost effectiveness, fast turnaround time, and high efficiency of xenotransplantation. LIDE's FGI (Functional Genomic Imaging) platform leverages its K-cell technology and bioinformatics team to deliver next-generation transcription analysis. The primary benefit of CR (Conditionally Reprogrammed) cells is their intratumor and intertumor heterogeneity, even after amplification. | Commercial Services |